RT Journal Article
SR Electronic
T1 Hypofractionated Stereotactic Radiotherapy with the Hypoxic Sensitizer AK-2123 (Sanazole) for Reirradiation of Brain Metastases: A Preliminary Feasibility Report
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1773
OP 1776
VO 33
IS 4
A1 HIDEYA YAMAZAKI
A1 SATOAKI NAKAMURA
A1 TAKUYA NISHIMURA
A1 NAOHIRO KODANI
A1 TAKUJI TSUBOKURA
A1 TAKUYA KIMOTO
A1 HIROYA SIHOMI
A1 NORIHIRO AIBE
A1 KEN YOSHIDA
A1 MASAHIKO KOIZUMI
A1 TSUTOMU KAGIYA
YR 2013
UL http://ar.iiarjournals.org/content/33/4/1773.abstract
AB Reirradiation is a challenging field in the treatment of recurrent brain metastases. Because of the elevated risk of radiation toxicity due to previous irradiation, only a limited dose is prescribed. To enhance radiosensitivity, in the present analysis six patients received hypofractionated stereotactic radiotherapy (hSRT) with daily oral administration of the hypoxic sensitizer AK-2123 (sanazole) for progressive brain metastases after previous radiotherapy. The patients received daily oral administration of 1.0 g/day sanazole up to 2 h before radiotherapy. Three partial and three stable responses were observed, with no sanazole-related toxicity, except for a case of mild nausea. Brain failure with subsequent death occurred in one patient. The other patients maintained good performance status until disease progression in other lesions. hSRT with a hypoxic radiation sensitizer appears to have the potential to enhance the efficacy of radiotherapy.